TransMedics Group's (TMDX) Hold Rating Reiterated at Needham & Company LLC

TransMedics Group (NASDAQ:TMDX - Get Free Report)'s stock had its "hold" rating reiterated by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Tuesday,Benzinga reports.

A number of other brokerages have also weighed in on TMDX. Oppenheimer increased their target price on TransMedics Group from $125.00 to $130.00 and gave the stock an "outperform" rating in a research note on Friday, May 9th. Canaccord Genuity Group restated a "buy" rating and set a $104.00 price target on shares of TransMedics Group in a report on Tuesday, March 11th. Finally, Piper Sandler reiterated an "overweight" rating and issued a $145.00 target price (up from $125.00) on shares of TransMedics Group in a report on Wednesday, June 4th. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $125.11.

TransMedics Group Stock Down 0.6%

Shares of TransMedics Group stock opened at $141.96 on Tuesday. TransMedics Group has a 1 year low of $55.00 and a 1 year high of $177.37. The business has a 50-day moving average of $110.23 and a two-hundred day moving average of $82.77. The company has a market capitalization of $4.80 billion, a P/E ratio of 151.02 and a beta of 2.10. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.29 by $0.41. The business had revenue of $143.54 million for the quarter, compared to analysts' expectations of $123.39 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The firm's revenue was up 48.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.35 EPS. As a group, equities analysts predict that TransMedics Group will post 1 EPS for the current year.

Insider Buying and Selling at TransMedics Group

In other news, Director David Weill sold 732 shares of the firm's stock in a transaction on Friday, May 23rd. The stock was sold at an average price of $123.88, for a total transaction of $90,680.16. Following the completion of the transaction, the director now directly owns 12,134 shares in the company, valued at $1,503,159.92. This trade represents a 5.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Anil P. Ranganath sold 686 shares of the company's stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $139.80, for a total transaction of $95,902.80. Following the completion of the transaction, the insider now owns 13,955 shares in the company, valued at approximately $1,950,909. This represents a 4.69% decrease in their position. The disclosure for this sale can be found here. Insiders sold 12,418 shares of company stock valued at $1,512,613 in the last quarter. Company insiders own 7.00% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TMDX. Van ECK Associates Corp lifted its position in shares of TransMedics Group by 102.3% during the 4th quarter. Van ECK Associates Corp now owns 1,997 shares of the company's stock valued at $125,000 after buying an additional 1,010 shares in the last quarter. Rhumbline Advisers boosted its stake in shares of TransMedics Group by 35.8% in the fourth quarter. Rhumbline Advisers now owns 90,061 shares of the company's stock worth $5,615,000 after acquiring an additional 23,742 shares during the period. J.W. Cole Advisors Inc. grew its position in shares of TransMedics Group by 20.7% during the fourth quarter. J.W. Cole Advisors Inc. now owns 12,384 shares of the company's stock worth $772,000 after purchasing an additional 2,127 shares in the last quarter. Baillie Gifford & Co. raised its stake in TransMedics Group by 14.9% during the 4th quarter. Baillie Gifford & Co. now owns 269,836 shares of the company's stock valued at $16,824,000 after purchasing an additional 34,947 shares during the period. Finally, State of New Jersey Common Pension Fund D lifted its holdings in TransMedics Group by 95.8% in the 4th quarter. State of New Jersey Common Pension Fund D now owns 25,316 shares of the company's stock worth $1,578,000 after purchasing an additional 12,387 shares in the last quarter. Institutional investors own 99.67% of the company's stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.